Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1668-1680

  Weiss, Matthew M ^a   Harmange, Jean Christophe ^a   Polverino, Anthony J ^a   Bauer, David ^a   Berry, Loren ^a   Berry, Virginia ^a   Borg, George ^a   Bready, James ^a   Chen, Danlin ^a   Choquette, Deborah ^a   Coxon, Angela ^a   DeMelfi, Tom ^a   Doerr, Nicholas ^a   Estrada, Juan ^a   Flynn, Julie ^a   Graceffa, Russell F ^a   Harriman, Shawn P ^a   Kaufman, Stephen ^b   La, Daniel S ^a   Long, Alexander ^a   Neervannan, Sesha ^a,c   Patel, Vinod F ^a   Potashman, Michele ^a   Regal, Kelly ^a   Roveto, Phillip M ^a   Schrag, Michael L ^a   Starnes, Charlie ^a   Tasker, Andrew ^a   Teffera, Yohannes ^a   Whittington, Douglas A ^a   Zanon, Roger ^a   more..

^a AMGEN INC   (United States)

^b Amgen Inc ^*

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (5 (CYCLOPROPYLCARBAMOYL)NAPHTHALENE 2 YLOXY) 7 METHOXYQUINOLINE 6 CARBOXAMIDE; 4 (5 CARBAMOYLNAPHTHALEN 2 YLOXY) 7 METHOXYQUINOLINE 6 CARBOXAMIDE; 4 [5 [(2METHOXYETHYL)CARBAMOYL]NAPHTHALENE 2 YLOXY] 7 METHOXYQUINOLINE 6 CARBOXAMIDE; 6 (6 CARBAMOYL 7 METHOXYQUINOLIN 4 YLOXY) 1 NAPHTHOIC ACID; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE METHANE SULFONATE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHOIC ACID; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (1 METHYLCYCLOPROPYL) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (2 METHOXYETHYL) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (2,2,2 TRICLUROETHYL) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (3 METHOXYETHYL) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N (3 METHOXYPROPYL) 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N ETHYL 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N ISOPROPYL 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N METHYL 1 NAPHTHAMIDE; 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) N PROPYL 1 NAPHTHAMIDE; 6 (7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHOIC ACID; 6 (7 METHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; 6 (7 METHOXYQUINOLIN 4 YLOXY) 1 NAPHTHOIC ACID; N (2 METHOXYETHYL) 6 (7 METHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; N (CYCLOPROPYLMETHYL) 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; N CYCLOBUTYL 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; N CYCLOPENTYL 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; N CYCLOPROPYL 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; N TERT BUTYL 6 (6,7 DIMETHOXYQUINOLIN 4 YLOXY) 1 NAPHTHAMIDE; NAPHTHAMIDE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 TYROSINE KINASE INHIBITOR; VASCULOTROPIN C;

ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG INHIBITION; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CORNEAL NEOVASCULARIZATION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHALENES; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 41149143717     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701098w     Document Type: Article

References (44)

1. (a) Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972, 175, 409-416.
2. (b) Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2, 795-803.
3. (a) Cherrington, J. M.; Strawn, L. M.; Shawver, L. K. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv. Cancer Res. 2000, 79, 1-38.
4. (b) Siemann, D. W.; Chaplin, D. J.; Horsman, M. R. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004, 100, 2491-2499.
5. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6, 389-395.
6. Rak, J.; Mitsuhashi, Y.; Bayko, L.; Filmus, J.; Shirasawa, S.; Sasazuki, T.; Kerbel, R. S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995, 55, 4575-4580.
7. Mukhopadhyay, D.; Knebelmann, B.; Cohen, H. T.; Ananth, S.; Sukhatme, V. P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 1997, 17, 5629-5639.
8. Shweiki, D.; Neeman, M.; Itin, A.; Keshet, E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 768-772.
9. Wiesmann, C.; Fuh, G.; Christinger, H. W.; Eigenbrot, C.; Wells, J. A.; de Vos, A. M. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997, 91, 695-704.
10. Terman, B. I.; Dougher-Vermazen, M.; Carrion, M. E.; Dimitrov, D.; Armellino, D. C.; Gospodarowicz, D.; Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187, 1579-1586.
11. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
12. (a) Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
13. (b) Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542-2550.
14. Adjei, A. A. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor. Clin. Lung Cancer 2007, 8 (Suppl. 2), S74-S78.
15. (a) Thomas, A. L.; Morgan, B.; Dreves, J.; Unger, C.; Wiedenmann, B.; Vanhoefer, U.; Laurent, D.; Dugan, M.; Steward, W. P. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin. Oncol. 2003, 30 (Suppl. 6), 32-38.
16. (b) Ryan, A. J.; Wedge, S. R. ZD6474, a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer 2005, 92 (Suppl. 1), S6-S13.
17. (c) Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46, 1116-1119.
18. (d) Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c] carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.
19. (e) Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
20. (f) Ruggeri, B.; Singh, J.; Gingrich, D.; Angeles, T.; Albom, M.; Chang, H.; Robinson, C.; Hunter, K.; Dobrzanski, P.; Jones-Bolin, S.; Aimone, L.; Klein-Szanto, A.; Herbet, J.-M.; Bono, F.; Schaeffer, P.; Casellas, P.; Bourie, B.; Pili, R.; Isaacs, J.; Ator, M.; Hudkins, R.; Vaught, J.; Mallamo, J.; Dionne, C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 2003, 63, 5978-5991.
21. (g) Beebe, J. S.; Jani, J. P.; Knauth, E.; Goodwin, P.; Higdon, C.; Rossi, A. M.; Emerson, E.; Finkelstein, M.; Floyd, E.; Harriman, S.; Atherton, J.; Hillerman, S.; Soderstrom, C.; Kou, K.; Gant, T.; Noe, M. C.; Foster, B.; Rastinejad, F.; Marx, M. A.; Schaeffer, T.; Whalen, P. M.; Roberts, W. G. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003, 63, 7301-7309.
22. (a) Mross, K.; Drevs, J.; Muller, M.; Medinger, M.; Marme, D.; Hennig, J.; Morgan, B.; Lebwohl, D.; Masson, E.; Ho, Y. Y.; Guenther, C.; Laurent, D.; Unger, C. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer 2005, 41, 1291-1299.
23. (b) Thomas, A. L.; Morgan, B.; Horsfield, M. A.; Higginson, A.; Kay, A.; Lee, L.; Masson, E.; Puccio-Pick, M.; Laurent, D.; Steward, W. P. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 4162-4171.
24. Rini, B. I. Sorafenib. Expert Opin. Pharmacother. 2006, 7, 453-461.
25. (a) Atkins, M.; Jones, C. A.; Kirkpatrick, P. Sunitinib maleate. Nat. Rev. Drug Discovery 2006, 5, 279-280.
26. (b) Fiedler, W.; Serve, H.; Doehner, H.; Schwittay, M.; Ottmann, O. G.; O'Farrell, A. M.; Bello, C. L.; Allred, R.; Manning, W. C.; Cherrington, J. M.; Louie, S. G.; Hong, W.; Brega, N. M.; Massimini, G.; Scigalla, P.; Berdel, W. E.; Hossfeld, D. K. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105 (3), 986-993.
27. Polverino, A.; Coxon, A.; Starnes, C.; Diaz, Z.; DeMelfi, T.; Wang, L.; Bready, J.; Estrada, J.; Cattley, R.; Kaufman, S.; Chen, D.; Gan, Y.; Kumar, G.; Meyer, J.; Neervannan, S.; Alva, G.; Talvenheimo, J.; Montestruque, S.; Tasker, A.; Patel, V.; Radinsky, R.; Kendall, R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006, 66, 8715-8721.
28. Daylight, version 4.41; Daylight Chemical Information Systems, Inc.: Irvine, CA, 1995.
29. Harmange, J.-C.; Weiss, M. M.; Germain, J.; Polverino, A. J.; Borg, G.; Bready, J.; Chen, D.; Choquette, D.; Coxon, A.; DeMelfi, T.; DiPietro, L.; Doerr, N.; Estrada, J.; Flynn, J.; Graceffa, R. F.; Harriman, S. P.; Kaufman, S.; La, D. S.; Long, A.; Martin, M. W.; Neervannan, S.; Patel, V. F.; Potashman, M.; Regal, K.; Roveto, P. M.; Schrag, M. L.; Starnes, C.; Tasker, A.; Teffera, Y.; Wang, L.; White, R. D.; Whittington, D.; Zanon, R. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J. Med. Chem. 2008, 51, 1649-1667.
30. Nigg, E. A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2001, 2, 21-32.
31. Palacios, E. H.; Weiss, A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004, 23, 7990-8000.
32. (a) He, M.; Kania, R. S.; Lou, J.; Zhou, R. Preparation of Naphthalenecarboxamides and Their Derivatives as New Antiangiogenic Agents. WO 2005/021553 A1, 2005.
33. (b) Potashman, M.; Kim, T.; Bellon, S.; Booker, S.; Cheng, Y.; Kim, J. L.; Tasker, A.; Xi, N.; Xu, S.; Harmange, J.-C.; Borg, G.; Weiss, M.; Hodous, B. L.; Graceffa, R.; Buckner, W. H.; Masse, C. E.; Choquette, D.; Martin, M. W.; Germain, J.; Dipietro, L. V.; Chaffee, S. C.; Nunes, J. J.; Buchanan, J. L.; Habgood, G. J.; McGowan, D. C.; Whittington, D. A. Preparation of Heteroaryl Substituted Naphthalenes as Inhibitors of Lck, VEGFR and/or HGF Related Activity. WO 2005/070891 A2, 2005.
34. De, D.; Krogstad, F. M.; Byers, L. D.; Krogstad, D. J. Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J. Med. Chem. 1998, 41, 4918-4926.
35. Lindley, J. Copper assisted nucleophilic substitution of aryl halogen. Tetrahedron 1984, 40, 1433-1456.
36. Nomoto, Y.; Obase, H.; Takai, H.; Hirata, T.; Teranishi, M.; Nakamura, J.; Kubo, K. Studies on cardiotonic agents. I. Synthesis of some quinazoline derivatives. Chem. Pharm. Bull. 1990, 38, 1591-1595.
37. Tan, H.; Semin, D.; Wacker, M.; Cheetham, J. An automated screening assay for determination of aqueous equilibrium solubility enabling SPR study during drug lead optimization. J. Assoc. Lab. Autom. 2005, 10 (6), 364-373.
38. (a) Shaffer, C. L.; Morton, M. D.; Hanzlik, R. P. Enzymatic N-dealkylation of an N-cyclopropylamine: an unusual fate for the cyclopropyl group. J. Am. Chem. Soc. 2001, 123, 349-350.
39. (b) Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug. Metab. 2005, 6, 161-225.
40. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; Baillie, T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004, 17, 3-16.
41. 14C.
42. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27, 1350-1359.
43. Miles, A. A.; Miles, E. M. Vascular reactions to histamine, histamine-liberator,and leukotaxine in the skin of guinea pigs. J. Physiol. 1952, 118, 228-257.
44. Coxon, A.; Bolon, B.; Estrada, J.; Kaufman, S.; Scully, S.; Rattan, A.; Duryea, D.; Hu, Y. L.; Rex, K.; Pacheco, E.; Van, G.; Zack, D.; Feige, U. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. 2002, 46, 2604-2612.